Commercial and market data benchmarks: share, access and uptake

• TRx (Total Prescriptions): all prescriptions filled for a drug in a period, new plus refills.
• NRx (New Prescriptions): first-time fills, a leading indicator of new patient starts and prescriber adoption.

Sales and claims data. Wholesaler and distributor data (from the "Big Three" US drug distributors: McKesson, Cencora, Cardinal Health) tracks units shipped into the channel, distinct from what's actually dispensed to patients. The gap between shipped and dispensed is called channel inventory, and it can distort short-term trends.

Payer and access data. Formulary data (which drugs an insurer covers, and under what conditions) comes from sources like MMIT (Managed Markets Insight and Technology) in the US, tracking tier placement, prior authorization requirements, and step therapy rules across commercial, Medicare, and Medicaid plans.

In Europe, equivalent commercial visibility is fragmented by country: IQVIA still operates nationally (Germany's statutory health insurance data, France's SNDS claims database, UK's IQVIA and NHS Business Services Authority prescribing data), but there is no single pan-European TRx equivalent. This fragmentation itself is a data-quality fact worth remembering: US benchmarks travel poorly to European market access discussions.

Reading the dashboard: TRx, NRx, and share

A worked example makes this concrete.

Suppose a brand records 10,000 TRx in a month, with 3,000 of those being NRx. The NRx/TRx ratio is 3,000 / 10,000 = 30%. Early in a launch, marketers want this ratio high (new patients driving volume). Two years post-launch, a healthy ratio might settle near 15 to 20%, reflecting a stable base of refills. If NRx share falls sharply while TRx holds steady, that's often a warning sign masked by refill inertia, new patient starts are drying up even though the topline volume looks fine.

Market shareMarket shareThe percentage of total industry sales your company captures in a given period. It measures competitive position relative to rivals in a defined market.View full definition → is usually calculated within a defined competitive set (a "molecule market" or "therapeutic class"). If total TRx across all competing branded drugs in a class is 100,000, and your brand has 10,000, your TRx share is 10%. Analysts also track NRx share separately since it reveals momentum before it shows up in TRx share, NRx share is the earlier signal because new prescriptions move faster than the slower-changing refill base.

Payer coverage and days-to-access benchmarks

Volume data tells you what's happening; access data tells you why.

Payer coverage rate is the percentage of covered lives (patients, weighted by insurance plan enrollment) for whom a drug is on formulary, at any tier. As a rough 2025-2026 US estimate, a newly launched specialty drug might reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → 40 to 50% covered-lives access within six months, climbing toward 70 to 80% by 18 to 24 months, figures that vary enormously by therapeutic area and are always estimates pending the specific payer landscape.

Prior authorization (PA) rate measures the share of covered lives requiring insurer pre-approval before dispensing. High PA burden (commonly over 50% for specialty oral drugs) slows uptake regardless of formulary status.

Days-to-formulary-access measures the lag between FDA approval (US Food and Drug Administration) or EMA approval (European Medicines Agency) and the point a plan or national health system actually lists the drug for reimbursement. In the US, major PBMs often take 60 to 90 days post-launch to finalize formulary decisions, though exclusive negotiated deals can extend this. In Europe, the lag is structurally longer and country-specific: Germany's AMNOG process (Arzneimittelneuordnungsgesetz, the law governing early benefit assessment and price negotiation) typically resolves within 6 to 12 months of launch, while the UK's NICE (National Institute for Health and Care Excellence) technology appraisal can take a similar window or longer before a positive recommendation translates into NHS funding.

A simple benchmark table commercial teams track monthly:

| Metric | What it signals | Rough healthy range (estimate) |

|---|---|---|

| NRx/TRx ratio | Growth vs. maturity | 30%+ at launch, 15-20% steady state |

| Covered lives access | Payer reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → | 40-50% by month 6, 70-80%+ by month 24 |

| PA rate | Access friction | Lower is better; varies by class |

| Days to formulary decision | Speed of access | 60-90 days (US); 6-12 months (EU, country-dependent) |

Data qualityData qualityThe degree to which data is fit for purpose: accurate, complete, consistent, timely, valid and unique. Poor quality data undermines analytics, reporting and AI.View full definition → issues unique to commercial pharma data

Three governance problems recur constantly.

Projection and sampling bias. IQVIA and similar vendors don't capture every pharmacy transaction; they project national totals from a sample, then apply statistical models to estimate the rest. This means two "TRx" numbers from different vendors, or the same vendor's revised figures, can legitimately differ by several percent. Never treat a single-source Rx count as an exact census.

Channel versus patient-level lag. Wholesaler shipment data reacts to inventory decisions (stocking ahead of a price increase, destocking before a formulary loss), not real patient demand. A spike in distributor sales data can precede or lag actual NRx trends by weeks.

Specialty pharmacy blind spots. Drugs dispensed through limited or exclusive specialty pharmacy networks (common for oncology and rare disease drugs) may be underreported in standard retail Rx panels, since specialty pharmacies don't always participate in the same data feeds. Analysts must cross-check against hub services data (patient support programs that track enrollment and fills directly) to fill the gap.

A basic sanity-check any analyst should run before presenting a share number:

Flagging discrepancies above roughly 5% before they reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → a slide deck is a basic governance habit, not a technical luxury.

Putting it together: a monthly review checklist

A disciplined market access or brand analytics team walks through the same sequence every reporting cycle:

1. Reconcile TRx/NRx across at least two vendor sources if budget allows (or flag single-source risk if not).

2. Separate channel/distributor data from patient-level dispensing data before drawing demand conclusions.

3. Cross-reference formulary status (MMIT or equivalent) against actual claims-level rejection and PA rates, since formulary listing doesn't guarantee frictionless access.

4. Track days-to-access against the specific regulatory and payer pathway (AMNOG timeline, NICE appraisal, US PBM formulary cycle) rather than a single generic benchmark.

5. Watch NRx share as the earliest signal of competitive momentum, before it shows up in TRx or revenue.

For a deeper primer on how claims data underpins these metrics, IQVIA publishes methodology overviews at iqvia.com, and CMS's own claims data resources at data.cms.gov are a free way to see US public payer claims structure firsthand.

🎬 [VIDEO: "How Pharmaceutical Sales Data Works (IQVIA, Prescription Data Explained)" - youtube.com - search for vendor or industry explainer videos covering how prescription claims data is aggregated and sold to pharma companies]

Key Takeaways

• TRx (total prescriptions) and NRx (new prescriptions) are the core volume metrics; NRx/TRx ratio and NRx share are earlier signals of momentum than TRx share or revenue.
• Payer coverage rate, prior authorization rate, and days-to-formulary-access measure friction between approval and real-world uptake, and these benchmarks differ structurally between the US (PBM-driven, 60-90 day formulary cycles) and Europe (country-specific processes like Germany's AMNOG or the UK's NICE, often 6-12 months).
• Commercial data is sampled and projected, not a census: cross-check vendor sources (IQVIA, Symphony/ICON, MMIT) and flag variances above roughly 5% before reporting.
• Channel (wholesaler/distributor) data reflects stocking behavior, not patient demand; always separate it from patient-level dispensing data.
• Specialty and rare disease drugs often have blind spots in standard retail Rx panels; hub services and patient support program data help close the gap.